Whether the regulation of NF-κB pathway in CD4+ T cells played an essential role in producing anti-tumor response to decitabine-primed chemotherapy in solid tumor patients, and exploring the potential role of β-TrCP as a biomarker in decitabine-mediated CD4+ T-cell activation in patients is worthy of our further investigation. This evidence concerns the gene BTRC and neoplasm.